Jane Winter MD

Hematologic Oncology

Professor in Medicine-Hematology/Oncology, Feinberg School of Medicine, Northwestern University

Summary

Dr. Jane Winter, MD is a Hematologist based in Chicago, IL, with a subspecialty in Hematologic Oncology. She has extensive experience in treating non-Hodgkin lymphoma and Hodgkin's lymphoma. Dr. Winter is trained in Hematology and Medical Oncology from McGaw Medical Center of Northwestern University and the New York Presbyterian Hospital. Her residency was undertaken in Internal Medicine at the University of Chicago and she is an alumnus of the Perelman School of Medicine at the University of Pennsylvania. Dr. Winter has contributed significantly to the field with numerous publications in Blood Advances, particularly on lymphomas and CAR-T therapy. She has extensive experience as a principal investigator for multiple clinical trials, working primarily with lymphoma treatments. Her consistent excellence in her field has earned her a host of honors including being recognized multiple times as one of "America's Top Doctors" by Castle Connolly.

McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 1981 - 1982
New York Presbyterian Hospital (Columbia Campus)Fellowship, Hematology and Medical Oncology, 1980 - 1981
University of ChicagoResidency, Internal Medicine, 1977 - 1980
Perelman School of Medicine at the University of PennsylvaniaClass of 1977

CMS Meaningful Use Stage 2 Certification Northwestern Meaningful Use Data Warehouse Application for Eligible Providers, Northwestern University, 2012-2017
CMS Meaningful Use Stage 1 Certification PowerChart, Cerner Corporation, 2012-2017
CMS Meaningful Use Stage 2 Certification PowerChart (Clinical), Cerner Corporation, 2012-2017

PubMed

1 citations
Outcomes for CART as 2L vs 3L vs 4L or beyond in aggressive B-cell lymphoma: real-world evidence from the ABC Consortium.
John S Wang, Brandon L Ellsworth, Megan Melody, Narendranath Epperla, Deborah Stephens
Blood Advances. 2026-02-10
Hodgkin Lymphoma, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology.
Ranjana H Advani, Christopher R Kelsey, Philippe Armand, Celeste M Bello, Cecil M Benitez
Journal of the National Comprehensive Cancer Network. 2026-02-01
1 citations
Outcomes of bispecific antibodies after CAR T-cell failure for large B-cell lymphoma: results from the ABC consortium.
Megan Melody, Natalie Grover, Stephanie Franco, Jason Romancik, Matthew Cortese
Blood Advances. 2026-01-13

Abstracts/Posters

A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ Lymphomas
Jane N. Winter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Brief Pembrolizumab(PEM) Monotherapy Results in Complete and Near Complete Responses in the Majority of Untreated Patients with Classical Hodgkin Lymphoma (cHL): A Mul...
Jane N. Winter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classi...
Jane N. Winter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

A Phase II Studyof Sequential Pembrolizumab (PEM) Followed By AVD for Frontline Treatment of Classical Hodgkin Lymphoma (CHL): Quantifying Response Following PEM Monot...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Steep Price for Surviving Childhood Lymphoma: Epigenetic AgingDecember 13th, 2022
New Data: The Drug Ibrutinib May Help Some Younger Mantle Cell Lymphoma Patients Avoid a Stem Cell TransplantDecember 12th, 2022
'Unparalleled Times' in Hematology, but Workforce Issues PersistSeptember 26th, 2022